On November 17, 2022 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, reported RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium) (Press release, Renovorx, NOV 17, 2022, View Source [SID1234624213]). RenovoTAMP is a unique therapy platform designed for targeted intra-arterial (IA) delivery of chemotherapy directly to tumors. This symposium was the 30th annual AIMsymposium and is being held November 14-17, 2022 at the New York Hilton.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations included:
Dr. Ripal Gandhi, Professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, presented "Advances in the Management of Pancreatic Cancer," and provided an overview of the clinical challenges of the standard-of-care treatment available to locally advanced pancreatic cancer (LAPC) patients. Systemic intravenous (IV) chemotherapy is considered the standard of care for LAPC and is often associated with debilitating side effects and may be ineffective in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy.
Dr. Gandhi highlighted the RenovoTAMP therapy platform’s potential as a targeted oncology option for LAPC patients. The presentation reviewed RenovoRx’s RR1 Phase I/II and RR2 Observational Registry studies and RenovoTAMP’s potential to increase chemotherapy delivery directly to the tumor to increase survival and reduce systemic toxicity. Dr. Gandhi also presented the mission and protocol behind the TIGeR-PaC study.
The Phase III TIGeR-PaC study is evaluating RenovoRx’s first product candidate, RenovoGem, to treat LAPC through RenovoTAMP’s intra-arterial delivery of gemcitabine, an FDA-approved chemotherapy. Study goals include the extension of patient survival, reduction of side effects associated with systemic chemotherapy, and improved quality of life for pancreatic cancer patients.
Dr. Christopher Laing, an interventional radiologist at Sutter Medical Group, presented "Animal Studies Using a Double-Balloon Catheter Leads to Interesting Discoveries Regarding the Mechanism of Chemoperfusion for Pancreatic Cancer." Dr. Laing’s presentation discusses how RenovoTAMP and its potential benefits can be better described and optimized based on important scientific findings using animal models. For example, while some investigators have demonstrated interest in forcing chemotherapy across the wall of the bile duct for the treatment of bile duct cancer, Dr. Laing describes animal experiments that demonstrate challenges to this approach. Dr. Laing further highlights the potential for RenovoTAMP in the bile duct patient population, similar to its use in pancreatic cancer therapy. Dr. Laing also discusses recent discoveries on how the drugs may traverse through the wall of the major blood vessels adjacent to the tumor to make RenovoTAMP work which could also pave the way for expanding the therapy platform to a wide array of therapeutic agents, even beyond small molecule chemotherapeutics.
"The AIMsymposium is an insightful conference that focuses on current issues and new techniques in interventional radiology and endovascular therapy," said Ramtin Agah, M.D., Chief Medical Officer and Founder of RenovoRx. "We appreciate both Dr. Gandhi and Dr. Laing highlighting our therapy platform and its potential treatment option for patients diagnosed with difficult-to-treat cancers, like pancreatic and bile duct tumors."
Dr. Agah added, "These presentations emphasize our team’s tremendous focus on refining RenovoTAMP as a potential, more targeted therapy for difficult-to-treat cancers. Results of our studies to date suggest that utilizing approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles via RenovoTAMP has the potential to increase their efficacy, improve safety, and widen therapeutic windows. We continue to push the understanding of the science behind our success. Our research has identified one of the major barriers to therapeutic success in the pancreatic cancer setting: these types of tumors do not have sufficient blood vessels that would normally deliver chemotherapy. The RenovoTAMP therapy may overcome that barrier by using pressure to force chemotherapy into the tissue."
About the Phase III TIGeR-PaC Clinical Trial
TIGeR-PaC is a randomized multi-center Phase III study using RenovoRx’s innovative therapy platform, RenovoTAMP (RenovoRx Trans-Arterial Micro-Perfusion). The study is evaluating the Company’s first product candidate, RenovoGemTM, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.
TIGeR-PaC is currently enrolling unresectable LAPC patients at several sites across the US. To learn more about the study and the participating clinical trial sites, visit View Source